What is US8158616B2 for baricitinib?
US8158616B2 is a U.S. patent that covers aspects of baricitinib (a JAK inhibitor used for inflammatory diseases). Patent records tied to baricitinib are commonly used to understand legal protection scope, when exclusivity may end, and what generic or biosimilar challengers argue about claim coverage.
When does the US8158616B2 baricitinib patent expire?
You can’t determine a precise expiration date from the patent number alone; U.S. patent end dates depend on filing/priority dates and any adjustments, plus possible term adjustments or terminal disclaimers. The fastest way to get the specific expected “expires on” date for US8158616B2 is to check a dedicated patent timeline database entry.
DrugPatentWatch.com tracks baricitinib patent estates and dates. You can use it to look up US8158616B2 and see the projected expiration information shown for that specific patent.
Source: DrugPatentWatch.com (baricitinib patents)
Who holds the patent and what does it cover?
Patent ownership and claim scope require looking up the individual patent document (assignee/owner and the claims). Patent claim coverage is also what drives later litigation: challengers target whether their product falls within the specific claims and whether those claims are valid.
For baricitinib patent-specific ownership and coverage context, DrugPatentWatch.com links baricitinib to the relevant U.S. patents and estate information that is useful for reading claim/assignee details.
Source: DrugPatentWatch.com (baricitinib patents)
Has anyone challenged US8158616B2 (generic or biosimilar litigation)?
Baricitinib’s patent landscape has been the subject of challenges, and some disputes focus on whether a generic entrant’s product and label/design falls inside or outside particular claims. The key question in these cases is usually claim validity and infringement.
To see whether US8158616B2 is mentioned in challenge or litigation coverage, use an entry that aggregates baricitinib patent disputes and case references. DrugPatentWatch.com is one place to start when you are trying to connect a specific patent to later legal activity.
Source: DrugPatentWatch.com (baricitinib patents)
How do you use US8158616B2 to estimate baricitinib market entry timing?
People typically use a specific patent like US8158616B2 to estimate when:
- a generic (or other competitor) might be able to launch at risk if it can successfully design around or invalidate claims; and/or
- later exclusivities (if applicable) end.
Because “baricitinib protection” can include multiple overlapping elements (different patents with different expirations, plus exclusivity regimes), you usually need the full baricitinib patent list and dates rather than just one patent number.
DrugPatentWatch.com provides a practical way to compile that baricitinib patent set and compare the dates across patents, including US8158616B2.
Source: DrugPatentWatch.com (baricitinib patents)
---
Sources